Business Wire

Wemade's New MMORPG 'MIR M: Vanguard & Vagabond' Launches Worldwide

Share

Wemade officially launched its MMORPG ‘MIR M: Vanguard & Vagabond’ (MIR M) in more than 170 countries across the globe on January 31, 2023.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230131005535/en/

To view this piece of content from mms.businesswire.com, please give your consent at the top of this page.

Wemade's New MMORPG 'MIR M: Vanguard & Vagabond' Launches Worldwide. (Graphic: Wemade)

‘MIR M’ is an MMORPG that recreated ‘The Legend of Mir 2’, Wemade’s representative intellectual property (IP) that received a lot of attention from global players and led the craze for K-games. MIR M maximizes the unique strategic performance of the original game with ‘grid battlegrounds’ that enhance the fun of tactical plays and 'quarter-views’ that allow users to easily identify the battle composition.

It also has a new growth system with a high degree of freedom called Mandala, which allows users to activate different states and customize characters in their own way. ‘Hidden Valley Capture’ and ‘Sabuk Castle Siege’ allow users to compete for economic rewards and power.

The game token 'DRONE' and governance token 'DOGMA' have been added to MIR M to create an 'inter-game economy' with MIR4. It will also launch NFT (Non-Fungible Token) trading service for game characters and items in the future.

Wemade is planning numerous events to celebrate the official launch of MIR M. It will hold special events like Party Dungeons and Dungeon Raids, give away various summon tickets and other items through daily check-in events, and more. Once ‘DOGMA’ and ‘DRONE’ are added to the ‘Fusion depot’ through the ‘Featured IMO’ after the official launch, the tokens will be given to ‘Reflect’ holders via airdrop events.

MIR M, which supports a total of 12 languages, can be downloaded from the Google Play Store, Apple App Store, and the official website.

More information on MIR M is available on the official website.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

Wemade Co., Ltd. (112040: KOSDAQ)
Yeonghyun Lee, PR Manager
yeonghyun@wemade.com

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

MarkLines Gen-AI Beta Version Released for Automotive Industry13.1.2026 02:00:00 EET | Press release

MarkLines Co., Ltd. (Headquarters: Minato-ku, Tokyo; President & CEO: Makoto Sakai; TYO:3901) announced its launch of the "MarkLines Gen-AI Beta Version," the new feature for B2B users in the automotive industry. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260112383839/en/ "MarkLines Gen-AI Beta Version" can take questions in natural language and instantly give highly reliable, relevant data drawn from MarkLines’ extensive automotive database (Image: MarkLines Co., Ltd.) This AI-powered feature enables users to ask questions in natural language and instantly receive highly reliable, relevant data drawn from MarkLines’ extensive automotive database. Moreover, the system analyzes this information by leveraging the rich content across its platform and delivers clear, concise, text-based insights. By combining trusted data with advanced analytical capabilities through generative AI, this service represents a first-of-its-kind

Australian Defence Force Secures Satellite Communications on SES IS-2212.1.2026 23:30:00 EET | Press release

Satellite communications solutions provider SES will provide secure uninterrupted satellite communications to the Australian Defence Force (ADF) for a minimum of 16 years thanks to a new extended agreement. The service will be provided via the SES Intelsat 22 satellite and an ultra-high frequency (UHF) military communications payload. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260112137182/en/ Assistant Secretary Space Systems Branch, Michael Hunt, formalizes contract negotiations for the through-life support of the IS-22 satellite with Rory Welch, senior vice-president of service delivery at SES Space and Defense. Photos: Corporal Annika Smit Under the renewed arrangement, SES will reposition the IS-22 satellite to a new orbital slot specified by the ADF, continuing a mission that has been the cornerstone of Australia’s secure military communications since IS-22’s launch in 2012. SES will build a dedicated ground segmen

NetApp Appoints Paul Fipps to the Board of Directors12.1.2026 23:05:00 EET | Press release

NetApp® (NASDAQ: NTAP), the intelligent data infrastructure company, today announced that Paul Fipps, President of Global Customer Operations at ServiceNow, has joined its Board of Directors. The board now has ten directors, nine of whom are independent, and 50% of whom have been appointed within the last five years. Fipps brings more than 20 years of experience driving technology-enabled growth and customer transformation. At ServiceNow, he currently leads global sales, customer success, partner ecosystems, and field operations. He previously served as EVP of Worldwide Sales at ServiceNow and as President of Under Armour Connected Fitness and Chief Experience Officer at Under Armour, overseeing global direct-to-consumer, connected fitness, and digital experiences. He also previously served on the advisory board of Quantum Metric. Fipps holds a B.S. in Information Systems, an MBA from the University of Baltimore, and is a graduate of The Wharton School’s Advanced Management Program. “P

FDA Accepts New Drug Application for Pimicotinib for the Treatment of Tenosynovial Giant Cell Tumor12.1.2026 21:00:00 EET | Press release

Merck, a leading science and technology company, announced today that the U.S. Food and Drug Administration (FDA) has accepted the company’s new drug application (NDA) for pimicotinib as a systemic treatment for patients with tenosynovial giant cell tumor (TGCT). The application is based on the primary results and longer-term follow-up of the global Phase 3 MANEUVER study, which demonstrated deep and durable tumor responses and meaningful improvements in clinical outcomes with pimicotinib. “With pimicotinib, we have an opportunity to significantly advance care for people living with TGCT, a painful and debilitating disease that has few effective and well-tolerated treatment options beyond surgery,” said David Weinreich, Global Head of R&D and Chief Medical Officer for the Healthcare business of Merck. “Based on clinical trial results showing not only a reduction in tumor burden, but also the ability to help alleviate symptoms like pain and stiffness in the global Phase 3 MANEUVER study

Fabentech receives Marketing Authorization for Ricimed®, an antidote against ricin poisoning12.1.2026 20:32:00 EET | Press release

Fabentech, a French biopharmaceutical company specializing in medical countermeasures against biological threats, today announces that it has been granted Marketing Authorization for Ricimed®, a treatment for ricin poisoning. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260112241557/en/ Ricimed - Fabentech Ricimed®, an antidote against one of the most toxic natural substances in the world In addition to supportive care, and in severe situations requiring immediate administration, Ricimed® represents a new therapeutic option for the management of acute ricin intoxication. Ricin, among the most dangerous naturally occurring substances, can cause death within hours or days regardless of the route of exposure, making it a major biological threat for many countries. Having demonstrated its ability to specifically target and neutralize ricin before irreversible damage occurs, Ricimed® is an antibody-based therapy relying on poly

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye